Regulation of Proteolytic activity to improve the recovery of Macrobrachium rosenbergii Nodavirus capsid protein

• Main Authors: Bethilda, A. S., Abdul Razak, M., Ho, K. L., Ng, C. L., Yong, Chean Yeah *, Tan, W. S.
• Format: Article
• Language: English
• Published: MDPI 2021
• Subjects: QR355 Virology
• Online Access: http://eprints.sunway.edu.my/1835/1/Yong%20Chean%20Yeah%20Regulation%20of%20proteolytic%20activity%20to%20improve%20the-ijms-22-08725.pdf; http://eprints.sunway.edu.my/1835/; http://doi.org/10.3390/ijms22168725; https://www.mdpi.com/1422-0067/22/16/8725

The causative agent of white tail disease (WTD) in the giant freshwater prawn is Macrobrachium rosenbergii nodavirus (MrNV). The recombinant capsid protein (CP) of MrNV was previously expressed in Escherichia coli, and it self-assembled into icosahedral virus-like particles (VLPs) with a diameter of approximately 30 nm. Extensive studies on the MrNV CP VLPs have attracted widespread attention in their potential applications as biological nano-containers for targeted drug delivery and antigen display scaffolds for vaccine developments. Despite their advantageous features, the recombinant MrNV CP VLPs produced in E. coli are seriously affected by protease degradations, which significantly affect the yield and stability of the VLPs. Therefore, the aim of this study is to enhance the stability of MrNV CP by modulating the protease degradation activity. Edman degradation amino acid sequencing revealed that the proteolytic cleavage occurred at arginine 26 of the MrNV CP. The potential proteases responsible for the degradation were predicted in silico using the Peptidecutter, Expasy. To circumvent proteolysis, specific protease inhibitors (PMSF, AEBSF and E-64) were tested to reduce the degradation rates. Modulation of proteolytic activity demonstrated that a cysteine protease was responsible for the MrNV CP degradation. The addition of E-64, a cysteine protease inhibitor, remarkably improved the yield of MrNV CP by 2.3-fold compared to the control. This innovative approach generates an economical method to improve the scalability of MrNV CP VLPs using individual protease inhibitors, enabling the protein to retain their structural integrity and stability for prominent downstream applications including drug delivery and vaccine development